Prognostic Implications of Gene Mutations in Acute Myeloid Leukemia With Normal Cytogenetics

Seminars in Oncology

Volumn 35, Issue 4, 2008, Pages 346-355

  Gaidzik, Verena ^a   Döhner, Konstanze ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CEBPA GENE; CYTOGENETICS; GENE MUTATION; GENOTYPE; HUMAN; NPM1 GENE; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS;

CCAAT-ENHANCER-BINDING PROTEINS; CYTOGENETICS; FMS-LIKE TYROSINE KINASE 3; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MUTATION; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PROGNOSIS;

EID: 48749123878     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.04.005     Document Type: Article

References (76)

1. Fröhling S., Scholl C., Gilliland D.G., et al. Genetics of myeloid malignancies-pathogenetic and clinical implications. J Clin Oncol 23 (2005) 6285-6295
2. Mrózek K., Heerema N.A., and Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 18 (2004) 115-136
3. Schlenk R.F., Benner A., Krauter J., et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 15 (2004) 3741-3750
4. Marcucci G., Mrózek K., Ruppero A.S., et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B Study. J Clin Oncol 23 (2005) 5705-5717
5. Tallman MS, Andersen JW, Schiffer CA, et al. All-transretinoic acid in acute promyelocytic leukemia. N Engl J Med. 337:1021-28
6. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21 (2003) 4642-4649
7. Estey E., and Döhner H. Acute myeloid leukaemia. Lancet 368 (2006) 1894-1907
8. Mrozek K., Heinonen K., and Bloomfield C.D. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Hematol 14 (2001) 19-47
9. Kelly L.M., and Gilliland D.G. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3 (2002) 179-198
10. Castilla L.H., Garret L., Adya N., et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet 23 (1999) 144-146
11. Yergeau D.A., Hetherington C.J., Wang Q., et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 15 (1997) 303-306
12. Song W.J., Sullivan M.G., Legare R.D., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23 (1999) 166-175
13. Smith M.L., Cavenhagh J.D., Lister T.A., et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351 (2004) 2403-2407
14. Kelly L.M., Kutok J.L., Williams I.R., et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A 99 (2002) 8283-8288
15. Schessl C., Rawat V.P., Cusan M., et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 115 (2005) 2159-2168
16. Gilliland D.G., and Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100 (2002) 1532-1542
17. Grisendi S., Mecucci C., Falini B., et al. Nucleophosmin and cancer. Nat Rev 6 (2006) 493-505
18. Falini B., Mecucci C., Tiacci E., et al. Gimema Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352 (2005) 254-266
19. + AML): biological and clinical features. Blood 109 (2007) 874-885
20. Döhner K., Schlenk R.F., Habdank M., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics-interaction with other gene mutations. Blood 106 (2005) 3740-3746
21. Verhaak R.G.W., Goudswaard C.S., van Putten W., et al. Mutations in nucleophosmin NPM1 in acute myeloid leukemia (AML): association with other genetic abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106 (2005) 3747-3754
22. Schnittger S., Schoch C., Kern W., et al. Nucleophosmin gene mutations are predictors of favourable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106 (2005) 3733-3739
23. Suzuki T., Kiyoi H., Ozeki K., et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 106 (2005) 2854-2861
24. Boissel N., Renneville A., Biggio V., et al. Relavence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 106 (2005) 3618-3620
25. Thiede C., Koch S., Creutzig E., et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107 (2006) 4011-4020
26. Gallagher R.E. Dueling mutations in normal karyotype AML. Blood 106 (2005) 3681-3682
27. Liu H., Tan B.C., Tseng K.H., et al. Nucleophosmin acts as a novel AP2alpha-binding transcriptional corepressor during cell differentiation. EMBO Rep 8 (2007) 394-400
28. Schlenk R.F., Fröhling S., Hartmann F., et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 18 (2004) 1798-1803
29. neg is a highly significant predictive factor for response to therapy with all-trans-retinoic acid in acute myeloid leukaemia-results from AMLSG trial AML HD98B. [abstract]. Blood 110 (2007) 297
30. Nakao M., Yokota S., Iwai T., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10 (1996) 1911-1918
31. Yamamoto Y., Kiyoi H., Nakano Y., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97 (2001) 2434-2439
32. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
33. Whitman S.P., Archer K.J., Feng L., et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 61 (2001) 7233-7239
34. Fröhling S., Schlenk R.F., Breitruck J., et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100 (2002) 4372-4380
35. Beran M, Luthra R, Kantarjian H, Estey E. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res. 204;28:547-50
36. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99 (2002) 4326-4335
37. Stirewalt D.L., and Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3 (2003) 650-665
38. Mead A.J., Linch D.C., Hills R.K., et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110 (2007) 1262-1270
39. Whitman S.P., Ruppert A.S., Radmacher M.D., et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplication. Blood 111 (2008) 1552-1559
40. Grundler R., Miething C., Thiede C., et al. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 105 (2005) 4792-4799
41. Mrózek K., Döhner H., and Bloomfield C.D. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol 14 (2007) 106-114
42. Fitzgibbon J., Smith L.L., Raghavan M., et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 65 (2005) 9152-9154
43. Gale R.E., Green C., Allen C., et al. The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111 (2008) 2776-2784
44. Stirewalt D.L., Kopecky K.J., Meshinchi S., et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 107 (2006) 3724-3726
45. Yanada M., Matsuo K., Suzuki T., et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 19 (2005) 1345-1349
46. Gale R.E., Hills R., Kottaridis P.D., et al. NO evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia from the UK MRC AML 10 and 12 trials. Blood 106 (2005) 3658-3665
47. Schlenk R.F., Döhner K., Krauter J., et al. Mutations and outcome of treatment in cytogenetically normal acute myeloid leukemia. N Engl J Med 358 (2008) 1909-1918
48. Stone R.M., DeAngelo D.J., Klimek V., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 (2005) 54-60
49. Smith B.D., Levis M., Beran M., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 (2004) 3669-3676
50. Fiedler W., Serve H., Döhner H., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
51. Pabst T., Mueller B.U., Zhang P., et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 3 (2001) 263-270
52. Fröhling S., Schlenk R.F., Stolze I., et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22 (2004) 624-633
53. Preudhomme C., Sagot C., Boissel N., et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100 (2002) 2717-2723
54. Barjesteh van Waalwijk van Doorn-Khosrovani S., Erpelinck C., Meijer J., et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 4 (2003) 31-40
55. Sellick G.S., Spendlove H.E., Catovsky D., et al. Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia 19 (2005) 1276-1278
56. Fröhling S., Schlenk R.F., Krauter J., et al. Acute myeloid leukemia with deletion 9q within a non-complex karyotype is associated with CEBPA loss-of-function mutations. Genes Chromosomes Cancer 42 (2005) 427-432
57. Strout M.P., Marcucci G., Bloomfield C.D., and Caligiuri M.A. The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. Proc Natl Acad Sci U S A 95 (1998) 2390-2395
58. Whitman S.P., Liu S., Vukosavljevic T., et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 106 (2005) 345-352
59. Döhner K., Tobis K., Ulrich R., et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group ULM (AMLSG Ulm). J Clin Oncol 20 (2002) 3254-3261
60. Caligiuri M.A., Strout M.P., Lawrence D., et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58 (1998) 55-59
61. Whitman S.P., Ruppert A.S., Marcucci G., et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood 109 (2007) 5164-5167
62. Stirewalt D.L., Kopecky K.J., Meshinchi S., et al. FLT3, RAS and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97 (2001) 3589-3595
63. Bacher U., Haferlach T., Schoch C., et al. Implication of NRAS mutations in AML: a study of 2502 patients. Blood 107 (2006) 3847-3853
64. Bowen D.T., Frew M.E., Hills R., et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 106 (2005) 2113-2119
65. Ellisen L.W., Carlesso N., Cheng T., et al. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 20 (2004) 1897-1909
66. King-Underwood L., Renshaw J., and Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 87 (1996) 2171-2179
67. Summers K., Stevens J., Kakkas I., et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 21 (2007) 550-551
68. Gaiger A., Schmid D., Heinze G., et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 12 (1998) 1886-1894
69. Mueller B.U., Pabst T., Osato M., et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 100 (2002) 998-1007
70. Döhner K., Tobis K., Bischof T., et al. Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: a study of the AML Study Group Ulm (AMLSG ULM). Blood 102 (2003) 3850
71. Vegesna V., Takeuchi S., Hofmann W.K., et al. C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res 26 (2002) 451-457
72. Lamandin C., Sagot C., Roumier C., et al. Are PU. 1 mutations frequent genetic events in acute myeloid leukemia (AML)? Blood 100 (2002) 4680-4681
73. Tartaglia M., Niemeyer C.M., Fragale A., et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34 (2003) 148-150
74. Xu R., Yu Y., Zheng S., et al. Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood 106 (2005) 3142-3149
75. Caliguri M.A., Briesewitz R., Yu J., Wang L., et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 110 (2007) 1022-1024
76. Sargin B., Choudhary C., Crosetto N., Schmidt M.H.H., et al. Flt3-dependent transformation by inactivating c-CBL mutations in AML. Blood 110 (2007) 1004-1012